Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Introduction: Eosinophilic COPD is an important inflammatory phenotype, but the mechanism is unknown. In this study we examine the migration of eosinophils in different inflammatory COPD phenotypes towards IL-5 and eotaxin which was unelucidated. Methods: Whole blood from 4 eosinophilic COPD patients, 4 non-eosinophilic COPD patients and 6 healthy controls was collected, with eosinophils isolated by ficoll-paque and dextran Methods Eosinophils were assessed for chemotactic ability. Briefly, eosinophils re-suspended at 1 χ 105 cells/ml were placed on a 3 µm pore membrane above solutions of IL-5 and eotaxin (50 ng/ml and 10 ng/ml respectively for one hour). Cells which passed through the membrane were treated with Cell-Titer-Glo solution to allow their detection by plate reader. Eosinophilic COPD was defined as patients with a peripheral blood eosinophil count of ≥2% of white blood cells. Results: Eosinophils from eosinophilic COPD patients showed significantly greater migration than both healthy controls towards IL-5 (median: 7021 cells, IQR: 6098–10 013 v median: 2288 cells, IQR: 1389–2702, p=0.0095) and non-eosinophilic COPD patients, (median: 3219 cells, IQR: 2488–3785, p=0.0286). Eosinophils from eosinophilic and non-eosinophilic patients (median: 5363 cells, IQR: 4101–5420 and median: 3683, IQR: 3091–4179 respectively) showed significantly greater migration towards eotaxin than healthy controls (median: 2304, IQR: 1519–2723. p=0.0238, p=0.038 respectively) (figure 1). Conclusion: Eosinophils in COPD show enhanced migration towards IL-5 and eotaxin. Whether this is a mechanism underlying T2 high COPD requires further investigation.

Original publication

DOI

10.1136/thoraxjnl-2017-210983.196

Type

Conference paper

Publisher

BMJ Publishing Group

Publication Date

15/11/2017